2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 820

Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination
Abstract Number: 1390

Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries – Implications for CV Risk Assessment
Abstract Number: 1963

Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis
Abstract Number: 389

High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis
Abstract Number: 2899

High Dose Aspirin for Treating Kawasaki Disease – Outdated Myth or Effective Aid?
Abstract Number: 1697

High Frequency Skin Ultrasound Detects Subclinical Diffuse Dermal Involvement in Patients with Limited Cutaneous Systemic Sclerosis
Abstract Number: 51

High Incidence of Non-Vertebral Osteoporotic Fracture and Hip Fracture in Brazilian Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study
Abstract Number: 795

High Interobserver Agreement on Ultrasonographic Findings in Patients with Large Vessel Vasculitis
Abstract Number: 1707

High Oxidative Stress in Fibrotic and Non-Fibrotic Skin of Patients with Systemic Sclerosis
Abstract Number: 56

High Prevalence of Cervical Malignant and Premalignant Lesions Among Women with Rheumatoid and Psoriatic Arthritis
Abstract Number: 2223

High Prevalence of Hepatitis C Virus Infection in a Japanese Inclusion Body Myositis Cohort
Abstract Number: 3008

High Prevalence of Subclinical Ultrasonographic Enthesopathy and Synovitis in Patients with Inflammatory Bowel Disease without Clinical Signs or Symptoms of Spondyloarthritis
Abstract Number: 1842

High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry
Abstract Number: 560

High Sensitivity of the ASAS Classification Criteria in Patients with HLA-B27 Positive Undifferentiated Spondyloarthritis with Onset of Disease after Age 45
Abstract Number: 1649

High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].